|
Back to Home » January 2020 News » Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies |
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies |
January 27, 2020
PARAMUS, N.J., Jan. 27, 2020 /PRNewswire/ -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to...
Source URL: https://www.prnewswire.com:443/news-releases/epygenix-therapeutics-successfully-completes-epx-100-phase-i-placebo-controlled-double-blind-2-period-study-and-ready-to-phase-2-studies-300993228.html
|
|
|
|
